Contest Trader

Don't miss the chance to cash-in prizes totaling

$10.000
Register here for the Ultimate demo trading competition

Pfizer has announced that its vaccine is 90% effective in preventing COVID-19 infection

Pfizer has announced that its vaccine is 90% effective in preventing COVID-19 infection

Late-stage trial data showed 90% effectiveness in preventing COVID-19 infection

Pfizer, alongside the German BioNTech, made a bold statement earlier today that impressed the markets.

According to the report published about their late-stage vaccine trial, their coronavirus vaccine is more than 90% effective in preventing COVID-19. The 90% effectiveness took people by storm, as scientists and researchers were hoping for a COVID-19 vaccine to be at least 75% effective.

The results came after an interim efficacy analysis that was conducted by an independent Data Monitoring Committee. The participants showed improvements one week after the administration of the second dose. Following the data, protection from COVID-19 is possible 28 days after the first vaccination. The whole procedure consists of two doses.

Even though the first results are promising, data regarding safety and various aspects of the vaccine are still being collected.

Wall Street was more than thrilled when hearing the news. USA30 surged 5.2%, while USA500 jumped 3.4%.

Sources: cnbc.com

This information prepared by za.capex.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.

This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent. Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of za.capex.com